RxDoctor Payments Data

Sita Devulapalli, MD

Internal Medicine · Longview, TXNPI 1578558904

Payments from drug & device makers

$1,385in general payments, 2019–2025

Across 87 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$445
  • Lilly USA, LLC$190
  • Bayer$108
  • Pfizer$84
  • Merck$78
  • Novo Nordisk$73
  • plus $407 from 13 others

What the payments were for

  • Food & beverage$1,385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,385 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$66,534
Medicare patients
190
Services billed
1,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$67,407
JanuviaSitagliptin Phosphate42$43,671
FarxigaDapagliflozin Propanediol45$31,578
AbrysvoRsv Vacc, Pref A And Pref B/Pf91$27,728
EliquisApixaban43$26,461
JanumetSitagliptin Phos/Metformin Hcl20$20,968
XareltoRivaroxaban19$18,967
ShingrixVaricella-Zoster Ge/As01b/Pf37$7,765
LinzessLinaclotide13$7,550
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$6,750
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,015
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide106$3,277
Pantoprazole Sodium241$2,595
PremarinEstrogens, Conjugated12$2,444
Celecoxib52$2,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$44$67,40761 claims
MerckJanuvia, Janumet$78$64,63962 claims
PfizerAbrysvo, Eliquis, Premarin$84$56,633146 claims
AstraZenecaFarxiga$445$31,57845 claims
AbbVieLinzess, Synthroid$66$8,46328 claims
GSKShingrix$15$7,76537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →